Delphine Boche, Claire Paquet, Jacques Hugon, James Nicoll on What About the Brain Shrinkage Seen with Aβ Removal?

COMMENT With currently available technology, it seems unlikely that the pathophysiology associated with Aβ immunotherapy-related atrophy can be understood without studying human brain tissue. That there has not been systematic postmortem follow-up of patients in

Delphine Boche, Claire Paquet, Jacques Hugon, James Nicoll on Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit

COMMENT Aβ immunotherapy has been considered as a treatment for Alzheimer’s disease for some years; however, the lack of clear cognitive efficiency associated with the presence of side effects in some patients has tempered enthusiasm. Nevertheless, the recent pub

Current Filters

TYPE: Comment x
Commentator: Hugon, Jacques x

Remove all filters

SEARCH RESULTS

Delphine Boche, Claire Paquet, Jacques Hugon, James Nicoll on What About the Brain Shrinkage Seen with Aβ Removal?

Delphine Boche, Claire Paquet, Jacques Hugon, James Nicoll on Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit

Current Filters

Filter By